Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NKTR NASDAQ:URGN NASDAQ:VERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNKTRNektar Therapeutics$24.79-0.6%$15.75$6.48▼$37.38$309.43M0.94523,809 shs583,097 shsURGNUrogen Pharma$15.46+1.2%$10.37$3.42▼$17.00$705.49M1.021.11 million shs2.31 million shsVERVVerve Therapeutics$10.93+0.2%$7.95$2.86▼$11.41$972.55M2.232.52 million shs2.24 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNKTRNektar Therapeutics0.00%-0.28%+193.07%+165.64%+19.62%URGNUrogen Pharma0.00%+7.23%+4.23%+58.07%-3.29%VERVVerve Therapeutics0.00%-1.09%-1.36%+128.24%+58.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNKTRNektar Therapeutics4.0817 of 5 stars3.42.00.04.23.32.50.0URGNUrogen Pharma4.3525 of 5 stars4.52.00.04.51.42.50.0VERVVerve Therapeutics2.9356 of 5 stars4.23.00.00.01.42.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNKTRNektar Therapeutics 2.86Moderate Buy$88.33256.33% UpsideURGNUrogen Pharma 3.00Buy$32.86112.53% UpsideVERVVerve Therapeutics 2.33Hold$14.5733.32% UpsideCurrent Analyst Ratings BreakdownLatest URGN, NKTR, and VERV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025NKTRNektar TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $85.007/8/2025URGNUrogen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.007/7/2025URGNUrogen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/27/2025VERVVerve TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$20.00 ➝ $13.506/26/2025VERVVerve TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/24/2025NKTRNektar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $100.006/24/2025NKTRNektar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$120.006/18/2025VERVVerve TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$28.00 ➝ $11.006/18/2025VERVVerve TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$12.006/18/2025VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$13.506/17/2025VERVVerve TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Market Perform(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNKTRNektar Therapeutics$98.43M3.13N/AN/A$4.94 per share5.02URGNUrogen Pharma$90.40M7.90N/AN/A($0.21) per share-73.62VERVVerve Therapeutics$32.33M30.14N/AN/A$5.83 per share1.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNKTRNektar Therapeutics-$118.96M-$9.600.00N/AN/A-152.49%-329.54%-55.24%8/6/2025 (Estimated)URGNUrogen Pharma-$126.87M-$3.180.00N/AN/A-150.68%-97,487.15%-49.57%8/12/2025 (Estimated)VERVVerve Therapeutics-$198.71M-$2.110.00N/AN/A-303.64%-35.81%-27.57%8/14/2025 (Estimated)Latest URGN, NKTR, and VERV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025NKTRNektar Therapeutics-$2.58N/AN/AN/AN/AN/A8/14/2025Q2 2025VERVVerve Therapeutics-$0.70N/AN/AN/A$4.26 millionN/A8/12/2025Q2 2025URGNUrogen Pharma-$0.85N/AN/AN/A$23.06 millionN/A5/14/2025Q1 2025VERVVerve Therapeutics-$0.71-$0.35+$0.36-$0.35$7.13 million$32.98 million5/12/2025Q1 2025URGNUrogen Pharma-$0.83-$0.92-$0.09-$0.92$22.71 million$20.25 million5/8/2025Q1 2025NKTRNektar Therapeutics-$2.70-$3.30-$0.60-$0.24$15.61 million$10.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNKTRNektar TherapeuticsN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNKTRNektar TherapeuticsN/A3.243.24URGNUrogen PharmaN/A5.655.47VERVVerve TherapeuticsN/A9.849.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNKTRNektar Therapeutics75.88%URGNUrogen Pharma91.29%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipNKTRNektar Therapeutics3.71%URGNUrogen Pharma4.70%VERVVerve Therapeutics19.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNKTRNektar Therapeutics22012.41 million11.95 millionOptionableURGNUrogen Pharma20046.20 million44.03 millionOptionableVERVVerve Therapeutics11089.14 million71.94 millionOptionableURGN, NKTR, and VERV HeadlinesRecent News About These Companies3 Bullish Biotech Stocks With Explosive Growth Trends...July 21 at 11:02 AM | marketbeat.comLilly’s $1 billion CRISPR bet: what Verve means for gene editingJuly 16, 2025 | thepharmaletter.comTGoldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (VERV)...July 15, 2025 | marketbeat.comBiotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.July 14, 2025 | msn.comBiotech Stocks Are Ready to Rebound. 3 to Watch Now.July 14, 2025 | msn.comTrump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.July 13, 2025 | hindustantimes.comHExperimental treatment for high cholesterol edits DNA in the body to reduce LDLJuly 11, 2025 | msn.comVerve Therapeutics Inc News (VERV) - Investing.comJuly 4, 2025 | investing.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Average Recommendation of "Hold" by AnalystsJuly 3, 2025 | marketbeat.comJune’s Busy Buyout Binge Bolsters M&A Stats for H1July 1, 2025 | biospace.comBBMO Capital Markets Downgrades Verve Therapeutics (NASDAQ:VERV) to HoldJune 28, 2025 | marketbeat.comBMO Capital Markets Reiterates Market Perform Rating for Verve Therapeutics (NASDAQ:VERV)June 27, 2025 | marketbeat.comVERV Verve Therapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comEli Lilly's Strategic Acquisition of Verve TherapeuticsJune 24, 2025 | pharmiweb.comPGAMMA Investing LLC Acquires 27,485 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)June 24, 2025 | marketbeat.comLilly To Acquire Verve For One-Time Cardiovascular TreatmentsJune 23, 2025 | insidermonkey.comWhy Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This WeekJune 20, 2025 | fool.com$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)June 20, 2025 | globenewswire.comEli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart DrugJune 19, 2025 | insidenova.comIVerve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3BJune 19, 2025 | msn.comVERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERVJune 18, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Bullish Biotech Stocks With Explosive Growth TrendsBy Chris Markoch | July 21, 2025View 3 Bullish Biotech Stocks With Explosive Growth TrendsBiotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsBy Nathan Reiff | June 30, 2025View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?By Leo Miller | June 28, 2025View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?URGN, NKTR, and VERV Company DescriptionsNektar Therapeutics NASDAQ:NKTR$24.79 -0.15 (-0.60%) Closing price 04:00 PM EasternExtended Trading$24.80 +0.01 (+0.04%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Urogen Pharma NASDAQ:URGN$15.46 +0.19 (+1.24%) Closing price 04:00 PM EasternExtended Trading$15.36 -0.10 (-0.61%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Verve Therapeutics NASDAQ:VERV$10.93 +0.02 (+0.18%) Closing price 04:00 PM EasternExtended Trading$10.98 +0.05 (+0.50%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Domino’s Delivers Another Discounted Entry for Income Investors TSLA Earnings Week: Can Tesla Break Through $350? Analysts See Upside in These 5 Stocks That Just Raised Dividends MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Kinder Morgan: At the Hotspot of the Natural Gas Revolution Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
